HER2/NEU NEGATIVE

This phase II trial studied 92 women with early-stage breast cancer to see how well chemotherapy (paclitaxel and cyclophosphamide) with or without trastuzumab works before surgery. The main goals were to check side effects and see if the tumor disappears completely by the time of…

This large phase III trial tests which of three chemotherapy drugs—paclitaxel, nab-paclitaxel, or ixabepilone—works best, with or without the targeted drug bevacizumab, for people with stage IIIC or IV breast cancer that has returned or spread. The study aims to find the most eff…

This phase II trial tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy carboplatin could help people with HER2-negative metastatic breast cancer that has spread. The 12 participants had cancer cells in their blood and had already tried …

This study looked at how well older adults (70+) with advanced, hormone-sensitive breast cancer tolerate a combination of palbociclib and either letrozole or fulvestrant. The goal was to see if the treatment is safe and effective in this age group. 93 participants were enrolled, …

This early-phase trial tested a new drug called ALRN-6924 combined with the chemotherapy paclitaxel in 28 adults with advanced solid tumors that had spread or couldn't be removed by surgery, including a type of breast cancer. The main goal was to find the safest dose and check fo…

This phase II trial tested the drug alisertib, alone or combined with fulvestrant, in 96 postmenopausal women with advanced breast cancer that no longer responds to hormone therapy. Alisertib blocks enzymes that help cancer cells grow, while fulvestrant blocks estrogen. The goal …

This phase II trial tested a combination of hormone therapy drugs (fulvestrant or an aromatase inhibitor) plus palbociclib in 14 elderly patients with hormone-responsive breast cancer who either had inoperable tumors or were too frail for surgery. The goal was to see if this drug…